ClinicalTrials.Veeva

Menu

Assessment of Asthma Control Level in Malaysia (ASCORE)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Asthma Control Level

Study type

Observational

Funder types

Industry

Identifiers

NCT03295331
D2287R00116

Details and patient eligibility

About

A Non-Interventional Retrospective Study To Assess The Level Of Asthma Control Among Adults at 2 Tertiary Care Centres In Malaysia; Institute Of Respiratory Medicine (IPR) And Hospital Serdang. The specific objective of the study is to assess, in real-life clinical practice in Malaysia, the level of GINA-defined asthma control and the potential risk factors for uncontrolled disease in asthma patients

Full description

Despite the availability of GINA global guideline on asthma management which is widely referred by health care providers in Malaysia, the control of asthma is still a critical challenge. According to National Health and Morbidity Survey 2011, the prevalence of asthma in Malaysia is at 6.3%. Based on self-rated health status, 5.5% of patients were reported to be in good health whereas 9.9% reported poor health status although medications such as inhaled corticosteroids (ICS) and long-acting beta agonists (LABA) are widely available for effective asthma management. There is limited data to assess the level of asthma control in Malaysia which includes current clinical manifestation and future risk of exacerbation. Given the lack of data on Asthma control level, the awareness on the current disease control level will assist to properly characterise the patients based on GINA control level thus leading to appropriate diagnosis and treatment. The specific objective of the study is to assess, in real-life clinical practice in Malaysia, the level of GINA-defined asthma control and the potential risk factors for uncontrolled disease in asthma patients

Enrollment

398 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016.
  • Be at least 18 years of age

Exclusion criteria

  • Clinical features suggesting emphysema or chronic bronchitis
  • Other de-compensated organ failures

Trial design

398 participants in 1 patient group

GINA-defined clinical diagnosis of Asthma
Description:
All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems